PositiveID highlights Firefly Dx in mid-year results

PostiiveID develops program for real-time molecular testing
PostiiveID develops program for real-time molecular testing

PositiveID Corp. released mid-year performance information to shareholders Monday that highlights the Firefly Dx's performance in testing.

The Firefly Dx is a hand-held device that uses polymerase chain reactions (PCR) to detect and identify pathogens. Among the devices' testing results, the company reports that it has been successful in the identification of multiple pathogen types with special, multiplex assays that allow the device to give up to four separate readings simultaneously. The device was also able to correctly identify the influenza virus despite identification requiring an additional reverse transcription step.

"As we reach the middle of 2015, we are very pleased with the advancements we’ve made to our Firefly Dx prototype system, and we will continue to expand our testing and challenge the system to present data to potential partners and future customers," PositiveID Chairman and CEO William Caragol said. “We believe that our accomplishments in the first half of 2015 set up PositiveID for continued exciting developments through the end of 2015 and into 2016 and are affirming our revenue guidance of $3 million to $6 million for 2015.”

PositiveID Corp. has also completed Joint U.S. Forces Korea Portal and Integrated Threat Recognition testing of the M-BAND, a detection system that was developed to meet biological threat detection needs of the government. The company also reported progress on the SenseNet contract with the Department of Homeland Security.